NEJM August 2026 Finerenone in Persons with Chronic Kidney Disease without Diabetes
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
NEJM August 2026 Finerenone in Persons with Chronic Kidney Disease without Diabetes
-
ナレーター：
-
著者：
This clinical study investigates whether the drug finerenone, previously proven effective for diabetic patients, can also protect the health of individuals with chronic kidney disease without diabetes. By tracking the rate of decline in kidney filtration over nearly three years, researchers discovered that those taking the medication experienced a significantly slower loss of renal functioncompared to those on a placebo. Beyond just preserving the kidneys, the treatment also demonstrated a measurable reduction in major cardiovascular and renal complications, such as heart failure or organ failure. While the therapy showed a slight increase in the risk of elevated potassium levels, the overall findings suggest that finerenone serves as a vital therapeutic option for a broader range of kidney patients than previously recognized.